Research programme: long noncoding RNA modulators - Eli Lilly and Company/Haya Therapeutics
Latest Information Update: 12 Sep 2024
At a glance
- Originator Eli Lilly and Company; HAYA Therapeutics
- Class Obesity therapies
- Mechanism of Action Long noncoding RNA modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Research Metabolic disorders; Obesity
Most Recent Events
- 04 Sep 2024 Eli Lilly and Company and Haya Therapeutics agree to co-develop Long noncoding RNA modulators for Obesity and Metabolic disorders in US and Switzerland
- 04 Sep 2024 Research programme: long noncoding RNA modulators - Eli Lilly and Company/Haya Therapeutics is available for licensing as of 04 Sep 2024. https://www.hayatx.com/approach
- 04 Sep 2024 Early research in Metabolic disorders in Switzerland (Parenteral)